Taken together, these results suggest that novel therapeutics targeting NF-κB may be of clinical utility in the treatment of advanced thyroid cancer, but this is not likely to be of global use in the treatment of all thyroid cancers. This evidence concerns the gene NFKB1 and thyroid gland carcinoma.